ストックスクリーナーアプリを入手
2.995
1.16%
-0.035
アフターアワーズ：
3.03
0.035
+1.17%
前日終値:
$3.03
開ける：
$3.07
24時間の取引高:
766.24K
Relative Volume:
0.84
時価総額：
$129.67M
収益：
$1.23M
当期純損益:
$-28.62M
株価収益率:
-1.9079
EPS:
-1.5698
ネットキャッシュフロー:
$-14.11M
1週間 パフォーマンス:
-9.79%
1か月 パフォーマンス:
-18.39%
6か月 パフォーマンス:
+24.27%
1年 パフォーマンス:
+2.92%
1日の値動き範囲:
$2.92
$3.09
1週間の範囲:
$2.92
$3.39
52週間の値動き範囲:
$1.62
$5.055
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Compare NRXP vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
2.995 | 131.19M | 1.23M | -28.62M | -14.11M | -1.5698 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-08 | 開始されました | H.C. Wainwright | Buy |
| 2025-04-02 | 開始されました | BTIG Research | Buy |
Nrx Pharmaceuticals Inc (NRXP) 最新ニュース
NRx Pharmaceuticals, Inc. (NRXP) Stock Price, News, Quote & History - Yahoo! Finance Canada
NRX Pharmaceuticals Inc. R (B1Q.F) Q1 FY2026 earnings call transcript - Yahoo Finance
NRx Pharmaceuticals, Inc. (NRXP) stock price, news, quote and history - Yahoo Finance UK
Why NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Is In Focus Now? - Kalkine Media
NRx Pharmaceuticals, Inc.(NasdaqCM: NRXP) added to S&P Global BMI Index - marketscreener.com
Should I Buy NRXP? NRXP 2026 AnalysisIntellectia AI™ - Intellectia AI
NRXP Q2 2026 Earnings: EPS Misses Estimate as Company Reports No RevenueNet Income Trends - careplusvn.com
NRx Pharmaceuticals’ ketamine ANDA amendment reclassified - Investing.com India
NRx Pharmaceuticals’ ketamine ANDA amendment reclassified By Investing.com - Investing.com Nigeria
NRX Pharmaceuticals (NRXP) FDA Amendment Reclassification Highli - GuruFocus
GeNeuro, Inc., an NRx Company is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis - marketscreener.com
NRx Pharmaceuticals Announces FDA Reclassification of ANDA Amendment for Preservative-Free Ketamine, Revises GDUFA Goal Date to November 10, 2026 - Quiver Quantitative
NRx Pharmaceuticals, Inc. Reports FDA First Cycle Review Of Preservative-Free Ketamine ANDA With No Drug Related Major Deficiencies And Begins Training And Deployment Of Zeta TMS AI Driven Robotic System In Treatment Of Suicidal Bipolar Depressi - marketscreener.com
Form 8K NRX Pharmaceuticals Inc For: 14 September By Investing.com - Investing.com India
NRx Pharmaceuticals: Promising Ketamine Opportunity In Psychiatry (NASDAQ:NRXP) - Seeking Alpha
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded - GlobeNewswire
NRXP's KETAFREE shows potential for commercial success pending FDA approval, making NRXP a speculative buy. - Pluang
FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP) - financialcontent.com
NRx deploys FDA-cleared robotic TMS system in Florida - grafa.com
NRXP: Preservative-free ketamine and robotic TMS drive innovation, with FDA decision expected soon - TradingView
NRx Pharmaceuticals at Cantor conference: ketamine push gains momentum By Investing.com - Investing.com Canada
NRx Pharmaceuticals Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System - Investing News Network
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System - marketscreener.com
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE - GlobeNewswire
NRX Pharmaceuticals Inc (NRXP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NRx Pharmaceuticals to Present at Three September Investor Conferences - citybiz
NRx Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
NRXP Stock Price, Quote & Chart - ChartMill
New to The Street's Prestigious Client NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine - The Ithaca Journal
NRx Pharmaceuticals (NASDAQ:NRXP) Downgraded by Zacks Research to Strong Sell - MarketBeat
H.C. Wainwright reiterates Buy on NRx Pharmaceuticals stock at $45 - Investing.com
H.C. Wainwright reiterates Buy on NRx Pharmaceuticals stock at $45 By Investing.com - Investing.com India
NRx Advances Ketamine Bid After FDA Review Clears Drug - MyChesCo
FDA First Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies Noted for Suicidal Bipolar Depression Treatment from NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - barchart.com
NRX (NRXP) Momentum: Ends Higher by 5.41% at $3.51 for the Current Session; the Current Price Sits Inside the Supplied Technical RangeIV Contraction - Vinanet
NRx cites arbitration in Kadima acquisition dispute - scanx.trade
Nrx Pharmaceuticals Earnings Call Signals Cautious Momentum - TipRanks
NRx Pharmaceuticals Targets 2026 KETAFREE Approval, Advances DARPA-Backed Depression Trial - citybiz
NRx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
BTIG Maintains NRX Pharmaceuticals(NRXP.US) With Buy Rating, Cuts Target Price to $10 - moomoo.com
BTIG Research Reaffirms "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP) - MarketBeat
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update - marketscreener.com
NRX Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
NRX Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
NRx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET - Investing News Network
NRX Pharmaceuticals Q2 Results: EPS Misses Estimate, Sales Fall 94% - scanx.trade
NRX Pharmaceuticals reports $18.0M net loss for first half 2026, $26.7M cash on hand - TradingView
Five million ketamine doses are in production—but when can sales start? - Stock Titan
Press Release: NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to Be Held on Monday, August 17th at 4:30pm ET - Moomoo
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET - Yahoo Finance
NRx Pharmaceuticals, Inc. (NRXP) reports Q2 loss, misses revenue estimates - FXStreet
Nrx Pharmaceuticals Inc (NRXP) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):